EFFECTIVENESS AND COST OF GENERIC VERSUS BRAND-NAME VALPROIC ACID
Saved in:
COULTER, D.L., EFFECTIVENESS AND COST OF GENERIC VERSUS BRAND-NAME VALPROIC ACID. MENTAL RETARDATION, Vol. 35, no. 6 (1997), p. 472-475.
Ref.
65295
Location:
SIIS R.101 Archivo
Palabras clave:
Crítica, Discapacidad, Discapacidad intelectual, Epilepsia, Fármacos
Crítica, Discapacidad, Discapacidad intelectual, Epilepsia, Fármacos
Similar Items: EFFECTIVENESS AND COST OF GENERIC VERSUS BRAND-NAME VALPROIC ACID
- EFFECTS OF SWITCHING FROM DEPAKENE TO GENERIC VALPROIC ACID ON INDIVIDUALS WITH MENTAL RETARDATION
- BONE MARROW SUPPRESSION INDUCED BY HIGH DOSE VALPROIC ACID
- VERAPAMIL AND VALPROIC ACID TREATMENT OF PROLONGED MANIA
- TRENDS IN THE USE AND ABUSE OF BRANDED AND GENERIC EXTENDED RELEASE OXYCODONOE AND FENTANYL PRODUCTS IN THE UNITED STATES
- WITHDRAWAL OF BARBITURATE ANTICONVULSANT DRUGS: PROSPECTIVE CONTROLLED STUDY
- SPECIALIST VERSUS GENERIC MODELS OF PSYCHIATRY TRAINING AND SERVICE PROVISION FOR PEOPLE WITH INTELLECTUAL DISABILITIES